Abstract
Peptide receptor radionuclide therapy (PRRT) is an expanding field with ¹⁷⁷Lu-Dotatate emerging as a treatment for midgut neuroendocrine tumours. Haematological side effects are infrequent, and the treatment is generally well tolerated. We present the case of a 70-year-old male patient who developed spontaneous bruising five weeks after his first dose of ¹⁷⁷Lu-Dotatate, with investigations consistent with disseminated intravascular coagulation (DIC). After initially requiring substantial transfusion support, the patient's DIC resolved with the commencement of corticosteroid therapy. This case suggests that DIC may be a rare subacute complication of ¹⁷⁷Lu-Dotatate, and that corticosteroids could be an effective component of management in such instances.